Thyroid hormone and cardiac disease: Frombasic concepts to clinical application

Journal of Thyroid Research

Volumn 2011, Issue , 2011, Pages

  Mourouzis, Iordanis ^a   Forini, Francesca ^b   Pantos, Constantinos ^a   Iervasi, Giorgio ^b  

^a UNIVERSITY OF ATHENS   (Greece)

^b INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BONE MORPHOGENETIC PROTEIN 4; DIIODOTHYROPROPIONIC ACID; FIBROBLAST GROWTH FACTOR 2; GROWTH FACTOR; LEVOTHYROXINE; LIOTHYRONINE; MAJOR HISTOCOMPATIBILITY ANTIGEN; MAMMALIAN TARGET OF RAPAMYCIN; NORADRENALIN; PHENYLEPHRINE; PHOSPHOLAMBAN; PLACEBO; PLATELET DERIVED GROWTH FACTOR; THYROID HORMONE; THYROID HORMONE DERIVATIVE; THYROID HORMONE RECEPTOR; THYROID RECEPTOR ALPHA 1; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ASTROCYTE; ATTITUDE TO HEALTH; CARDIAC PATIENT; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CELL DEDIFFERENTIATION; CELL DIFFERENTIATION; CELL FUNCTION; CELL REDIFFERENTIATION; CELL REGENERATION; CONGESTIVE HEART FAILURE; DRUG ACTIVITY; DRUG TOLERABILITY; EUTHYROIDISM; EVOLUTION; FEAR; GENE; GENETIC MANIPULATION; HEART DISEASE; HEART FAILURE; HEART FUNCTION; HEART HYPERTROPHY; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE; HEART MUSCLE CELL; HEART OUTPUT; HEART VENTRICLE REMODELING; HEMODYNAMICS; HOPE; HORMONE ACTION; HORMONE DEFICIENCY; HUMAN; ISCHEMIC HEART DISEASE; LOW LIOTHYRONINE SYNDROME; METAMORPHOSIS; MORBIDITY; NONHUMAN; OLIGODENDROGLIA; OUTCOME ASSESSMENT; OXYGEN CONSUMPTION; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SALT INTAKE; SIGNAL TRANSDUCTION; TH GENE;

EID: 84867555024     PISSN: 20908067     EISSN: 20420072     Source Type: Journal    
DOI: 10.4061/2011/958626     Document Type: Review

References (95)

1. H. Taegtmeyer, S. Sen, and D. Vela, "Return to the fetal gene program: a suggested metabolic link to gene expression in the heart", Annals of the New York Academy of Sciences, vol. 1188, pp. 191-198, 2010.
2. C. Pantos, I. Mourouzis, and D. V. Cokkinos, "New insights into the role of thyroid hormone in cardiac remodeling: time to reconsider?" Heart Failure Reviews, vol. 16, no. 1, pp. 79-96, 2011.
3. Y.-K. Lee, K.-M. Ng, Y.-C. Chan et al., "Triiodothyronine promotes cardiac differentiation and maturation of embryonic stem cells via the classical genomic pathway", Molecular Endocrinology, vol. 24, no. 9, pp. 1728-1736, 2010.
4. B. Swynghedauw, "Molecular mechanisms of myocardial remodeling", Physiological Reviews, vol. 79, no. 1, pp. 215-262, 1999. (Pubitemid 29056953)
5. M. Rajabi, C. Kassiotis, P. Razeghi, and H. Taegtmeyer, "Return to the fetal gene programprotects the stressed heart: a strong hypothesis", Heart Failure Reviews, vol. 12, no. 3-4, pp. 331-343, 2007. (Pubitemid 350176706)
6. C. Pantos, I. Mourouzis, A. Dimopoulos et al., "Enhanced tolerance of the rat myocardium to ischemia and reperfusion injury earlyafter acute myocardial infarction", Basic Research in Cardiology, vol. 102, no. 4, pp. 327-333, 2007. (Pubitemid 46909711)
7. C. Pantos, I. Mourouzis, T. Saranteas et al., "Thyroid hormone receptors α1 and β1 are downregulated in the post-infarcted rat heart: consequences on the response to ischaemiareperfusion", Basic Research in Cardiology, vol. 100, no. 5, pp. 422-432, 2005. (Pubitemid 41300497)
8. S. J. Odelberg, "Inducing cellular dedifferentiation: a potential method for enhancing endogenous regeneration in mammals", Seminars in Cell and Developmental Biology, vol. 13, no. 5, pp. 335-343, 2002. (Pubitemid 35300810)
9. A. Sáanchez Alvarado, "Regeneration in the metazoans: why does it happen?" BioEssays, vol. 22, no. 6, pp. 578-590, 2000.
10. E. R. Porrello, A. I. Mahmoud, E. Simpson et al., "Transient regenerative potential of the neonatal mouse heart", Science, vol. 331, no. 6020, pp. 1078-1080, 2011.
11. N. J. Oviedo and W. S. Beane, "Regeneration: the origin of cancer or a possible cure?" Seminars in Cell and Developmental Biology, vol. 20, no. 5, pp. 557-564, 2009.
12. J. F. Gudernatsch, "Feeding experiments on tadpoles-I: the influence of specific organs given as food on growth and differentiation. A contribution to the knowledge of organs with internal secretion", DevelopmentGenes and Evolution, vol. 35, no. 3, pp. 457-483, 1912.
13. M. Paris, F. Brunet, G. V. Markov, M. Schubert, and V. Laudet, "The amphioxus genome enlightens the evolution of the thyroid hormone signaling pathway", Development Genes and Evolution, vol. 218, no. 11-12, pp. 667-680, 2008.
14. J. M. W. Slack, G. Lin, and Y. Chen, "Molecular and cellular basis of regeneration and tissue repair: the Xenopus tadpole: a new model for regeneration research", Cellular and Molecular Life Sciences, vol. 65, no. 1, pp. 54-63, 2008.
15. O. Chassande, "Do unliganded thyroid hormone receptors have physiological functions?" Journal of Molecular Endocrinology, vol. 31, no. 1, pp. 9-20, 2003. (Pubitemid 37063075)
16. Y. Sato, D. R. Buchholz, B. D. Paul, and Y. B. Shi, "A role of unliganded thyroid hormone receptor in postembryonic development in Xenopus laevis", Mechanisms of Development, vol. 124, no. 6, pp. 476-488, 2007. (Pubitemid 46783879)
17. J. D. Furlow and E. S. Neff, "A developmental switch induced by thyroid hormone: Xenopus laevis metamorphosis", Trends in Endocrinology and Metabolism, vol. 17, no. 2, pp. 40-47, 2006.
18. M. Rolfe, L. E. McLeod, P. F. Pratt, and C. G. Proud, "Activation of protein synthesis in cardiomyocytes by the hypertrophic agent phenylephrine requires the activation of ERK and involves phosphorylation of tuberous sclerosis complex 2(TSC2)", Biochemical Journal, vol. 388, no. 3, pp. 973-984, 2005. (Pubitemid 40941586)
19. C. Pantos, C. Xinaris, I. Mourouzis et al., "Thyroid hormone receptor α1: a switch to cardiac cell "metamorphosis"?" Journal of Physiology and Pharmacology, vol. 59, no. 2, pp. 253-269, 2008. (Pubitemid 351955751)
20. C. Pantos, I. Mourouzis, G. Galanopoulos et al., "Thyroid hormone receptor 1 downregulation in postischemic heart failure progression: the potential role of tissue hypothyroidism", Hormone and Metabolic Research, vol. 42, no. 10, pp. 718-724, 2010.
21. K. Kinugawa, M. Y. Jeong, M. R. Bristow, and C. S. Long, "Thyroid hormone induces cardiac myocyte hypertrophy in a thyroid hormone receptor α1-specific manner that requires TAK1 and p38 mitogen-activated protein kinase", Molecular Endocrinology, vol. 19, no. 6, pp. 1618-1628, 2005. (Pubitemid 41002990)
22. 2+ handling and contraction in cardiomyocytes from mice with a dominant negative thyroid hormone receptor α", Journal of Molecular and Cellular Cardiology, vol. 38, no. 4, pp. 655-663, 2005. (Pubitemid 40461829)
23. C. Pantos, I. Mourouzis, and D. V. Cokkinos, "Thyroid hormone as a therapeutic option for treating ischaemic heart disease: from early reperfusion to late remodelling", Vascular Pharmacology, vol. 52, no. 3-4, pp. 157-165, 2010.
24. K. K. Henderson, S. Danzi, J. T. Paul, G. Leya, I. Klein, and A. M. Samarel, "Physiological replacement of T3 improves left ventricular function in an animal model of myocardial infarction-induced congestive heart failure", Circulation: Heart Failure, vol. 2, no. 3, pp. 243-252, 2009.
25. Y. F. Chen, S. Kobayashi, J. Chen et al., "Short term triiodo-L-thyronine treatment inhibits cardiac myocyte apoptosis in border area after myocardial infarction in rats", Journal of Molecular and Cellular Cardiology, vol. 44, no. 1, pp. 180-187, 2008.
26. C. Pantos, I. Mourouzis, K. Markakis et al., "Thyroid hormone attenuates cardiac remodeling and improves hemodynamics early after acute myocardial infarction in rats", European Journal of Cardio-thoracic Surgery, vol. 32, no. 2, pp. 333-339, 2007. (Pubitemid 47021454)
27. C. Pantos, I. Mourouzis, K. Markakis, N. Tsagoulis, M. Panagiotou, and D. V. Cokkinos, "Long-term thyroid hormone administration reshapes left ventricular chamber and improves cardiac function after myocardial infarction in rats", Basic Research in Cardiology, vol. 103, no. 4, pp. 308-318, 2008.
28. F. Forini, V. Lionetti, H. Ardehali et al., "Early long-term LT3 replacement rescues mitochondria and prevents ischemic cardiac remodelling in rats", Journal of Cellular and Molecular Medicine, vol. 15, no. 3, pp. 514-524, 2011.
29. C. Kalofoutis, I. Mourouzis, G. Galanopoulos et al., "Thyroid hormone can favorably remodel the diabetic myocardium after acute myocardial infarction", Molecular and Cellular Biochemistry, vol. 345, no. 1-2, pp. 161-169, 2010.
30. C. Pantos, I. Mourouzis, N. Tsagoulis et al., "Thyroid hormone at supra-physiological dose optimizes cardiac geometry and improves cardiac function in rats with old myocardial infarction", Journal of Physiology and Pharmacology, vol. 60, no. 3, pp. 49-56, 2009.
31. A. W. Linnane and H. Eastwood, "Cellular redox regulation and prooxidant signaling systems: a new perspective on the free radical theory of aging", Annals of the New York Academy of Sciences, vol. 1067, no. 1, pp. 47-55, 2006. (Pubitemid 43806309)
32. A. S. R. Araujo, P. Schenkel, A. T. Enzveiler et al., "The role of redox signaling in cardiac hypertrophy induced by experimental hyperthyroidism", Journal of Molecular Endocrinology, vol. 41, no. 5-6, pp. 423-430, 2008.
33. C. Pantos, Ch. Xinaris, I. Mourouzis, V. Malliopoulou, E. Kardami, and D. V. Cokkinos, "Thyroid hormone changes cardiomyocyte shape and geometry via ERK signaling pathway: potential therapeutic implications in reversing cardiac remodeling?" Molecular and Cellular Biochemistry, vol. 297, no. 1-2, pp. 65-72, 2007. (Pubitemid 46443530)
34. C. Pantos, V. Malliopoulou, I. Mourouzis et al., "Thyroxine pretreatment increases basalmyocardial heat-shock protein 27 expression and accelerates translocation and phosphorylation of this protein upon ischaemia", European Journal of Pharmacology, vol. 478, no. 1, pp. 53-60, 2003. (Pubitemid 38366075)
35. C. Pantos, V. Malliopoulou, I. Mourouzis et al., "Hyperthyroid hearts display a phenotype of cardioprotection against ischemic stress: a possible involvement of heat shock protein 70", Hormone and Metabolic Research, vol. 38, no. 5, pp. 308-313, 2006. (Pubitemid 43864951)
36. C. I. Pantos, V. A. Malliopoulou, I. S. Mourouzis et al., "Longterm thyroxine administration protects the heart in a pattern similar to ischemic preconditioning", Thyroid, vol. 12, no. 4, pp. 325-329, 2002. (Pubitemid 34438937)
37. A. Shulga, A. Blaesse, K. Kysenius et al., "Thyroxin regulates BDNF expression to promote survival of injured neurons", Molecular and Cellular Neuroscience, vol. 42, no. 4, pp. 408-418, 2009.
38. G. J. Kahaly and W. H. Dillmann, "Thyroid hormone action in the heart", Endocrine Reviews, vol. 26, no. 5, pp. 704-728, 2005. (Pubitemid 41127279)
39. B. Biondi and D. S. Cooper, "The clinical significance of subclinical thyroid dysfunction", Endocrine Reviews, vol. 29, no. 1, pp. 76-131, 2008. (Pubitemid 351252748)
40. I. Klein and K. Ojamaa, "Thyroid hormone and the cardiovascular system", The New England Journal of Medicine, vol. 344, no. 7, pp. 501-509, 2001. (Pubitemid 32164903)
41. M. Gomberg-Maitland and W. H. Frishman, "Thyroid hormone and cardiovascular disease", American Heart Journal, vol. 135, no. 2, pp. 187-196, 1998. (Pubitemid 28139156)
42. M. A. Hamilton, L. W. Stevenson, M. Luu, and J. A. Walden, "Altered thyroid hormone metabolism in advanced heart failure", Journal of the American College of Cardiology, vol. 16, no. 1, pp. 91-95, 1990. (Pubitemid 20217047)
43. C. Opasich, F. Pacini, N. Ambrosino et al., "Sick euthyroid syndrome in patients with moderate-to-severe chronic heart failure", European Heart Journal, vol. 17, no. 12, pp. 1860-1866, 1996. (Pubitemid 26413920)
44. A. Pingitore, P. Landi, M. C. Taddei, A. Ripoli, A. L'Abbate, and G. Iervasi, "Triiodothyronine levels for risk stratification of patients with chronic heart failure", American Journal of Medicine, vol. 118, no. 2, pp. 132-136, 2005. (Pubitemid 40202859)
45. D. D. Ascheim and K. Hryniewicz, "Thyroid hormone metabolism in patients with congestive heart failure: the low triiodothyronine state", Thyroid, vol. 12, no. 6, pp. 511-515, 2002. (Pubitemid 34721549)
46. L. Wartofsky and K. D. Burman, "Alterations in thyroid function in patients with systemic illness: the "euthyroid sick syndrome"", Endocrine Reviews, vol. 3, no. 2, pp. 164-217, 1982.
47. R. D. Utiger, "Altered thyroid function in nonthyroidal illness and surgery. To treat or not to treat?" The New England Journal of Medicine, vol. 333, no. 23, pp. 1562-1563, 1995.
48. i of human cardiomyocytes in culture", Cardiovascular Research, vol. 51, no. 2, pp. 322-330, 2001. (Pubitemid 32695543)
49. L. Friberg, S. Werner, G. Eggertsen, and S. Ahnve, "Rapid down-regulation of thyroid hormones in acute myocardial infarction: is it cardioprotective in patients with angina?" Archives of Internal Medicine, vol. 162, no. 12, pp. 1388-1394, 2002. (Pubitemid 34655199)
50. E. Galli, A. Pingitore, and G. Iervasi, "The role of thyroid hormone in the pathophysiology of heart failure: clinical evidence", Heart Failure Reviews, vol. 15, no. 2, pp. 155-169, 2010.
51. L. Ceremuzyński, A. Górecki, L. Czerwosz et al., "Low serum triiodothyronine in acute myocardial infarction indicates major heart injury", Kardiologia Polska, vol. 60, no. 5, pp. 468-480, 2004. (Pubitemid 38724835)
52. G. Kozdag, D. Ural, A. Vural et al., "Relation between free triiodothyronine/free thyroxine ratio, echocardiographic parameters and mortality in dilated cardiomyopathy", European Journal of Heart Failure, vol. 7, no. 1, pp. 113-118, 2005. (Pubitemid 40092502)
53. G. Iervasi, A. Pingitore, P. Landi et al., "Low-T3 syndrome: a strong prognostic predictor of death in patients with heart disease", Circulation, vol. 107, no. 5, pp. 708-713, 2003. (Pubitemid 36222598)
54. G. Iervasi, S. Molinaro, P. Landi et al., "Association between increased mortality and mild thyroid dysfunction in cardiac patients", Archives of Internal Medicine, vol. 167, no. 14, pp. 1526-1532, 2007. (Pubitemid 47124183)
55. P. W. Ladenson, S. I. Sherman, K. L. Baughman, P. E. Ray, and A. M. Feldman, "Reversible alterations in myocardial gene expression in a young man with dilated cardiomyopathy and hypothyroidism", Proceedings of the National Academy of Sciences of the United States of America, vol. 89, no. 12, pp. 5251-5255, 1992.
56. W. S. Colucci, "Molecular and cellularmechanisms of myocardial failure", The American Journal of Cardiology, vol. 80, no. 11A, pp. 15L-25L, 1997.
57. W. I. Khalife, YI. D. Tang, J. A. Kuzman et al., "Treatment of subclinical hypothyroidism reverses ischemia and prevents myocyte loss and progressive LV dysfunction in hamsters with dilated cardiomyopathy", American Journal of Physiology, vol. 289, no. 6, pp. H2409-H2415, 2005. (Pubitemid 41698550)
58. N. Tribulova, V. Knezl, A. Shainberg, S. Seki, and T. Soukup, "Thyroid hormones and cardiac arrhythmias", Vascular Pharmacology, vol. 52, no. 3-4, pp. 102-112, 2010.
59. I. Klein and S. Danzi, "Thyroid disease and the heart", Circulation, vol. 116, no. 15, pp. 1725-1735, 2007. (Pubitemid 47537847)
60. G. J. Kahaly, C. Kampmann, and S. Mohr-Kahaly, "Cardiovascular hemodynamics and exercise tolerance in thyroid disease", Thyroid, vol. 12, no. 6, pp. 473-481, 2002. (Pubitemid 34721543)
61. B. Biondi, E. A. Palmieri, S. Fazio et al., "Endogenous subclinical hyperthyroidism affects quality of life and cardiac morphology and function in young and middle-aged patients", Journal of Clinical Endocrinology and Metabolism, vol. 85, no. 12, pp. 4701-4705, 2000. (Pubitemid 32157655)
62. G. J. Kahaly, J. Nieswandt, S. Wagner, J. Schlegel, S. Mohr-Kahaly, and G. Hommel, "Ineffective cardiorespiratory function in hyperthyroidism" , Journal of Clinical Endocrinology and Metabolism, vol. 83, no. 11, pp. 4075-4078, 1998. (Pubitemid 28513598)
63. L. W. Hu, L. A. Benvenuti, E. A. Liberti, M. S. Carneiro-Ramos, and M. L. M. Barreto-Chaves, "Thyroxine-induced cardiac hypertrophy: influence of adrenergic nervous system versus renin-angiotensin system on myocyte remodeling", American Journal of Physiology, vol. 285, no. 6, pp. R1473-R1480, 2003. (Pubitemid 37464407)
64. S. P. Barry, S. M. Davidson, and P. A. Townsend, "Molecular regulation of cardiac hypertrophy", International Journal of Biochemistry and Cell Biology, vol. 40, no. 10, pp. 2023-2039, 2008.
65. G. Kaminski, D. Michalkiewicz, K. Makowski et al., "Prospective echocardiographic evaluation of patients with endogenous subclinical hyperthyroidism and after restoring euthyroidism", Clinical Endocrinology, vol. 74, no. 4, pp. 501-507, 2011.
66. R. M. Abdulrahman, V. Delgado, A. C. T. Ng et al., "Abnormal cardiac contractility in long-term exogenous subclinical hyperthyroid patients as demonstrated by two-dimensional echocardiography speckle tracking imaging", European Journal of Endocrinology, vol. 163, no. 3, pp. 435-441, 2010.
67. B. Biondi, "Invited commentary: cardiovascular mortality in subclinical hyperthyroidism: an ongoing dilemma", European Journal of Endocrinology, vol. 162, no. 3, pp. 587-589, 2010.
68. T. Vadiveloo, P. T. Donnan, L. Cochrane, and G. P. Leese, "The thyroid epidemiology, audit, and research study (TEARS): the natural history of endogenous subclinical hyperthyroidism", Journal of Clinical Endocrinology and Metabolism, vol. 96, no. 1, pp. E1-E8, 2011.
69. J. V. Parle, P. Maisonneuve, M. C. Sheppard, P. Boyle, and J. A. Franklyn, "Prediction of all-cause and cardiovascular mortality in elderly people from one low serum thyrotropin result: a 10-year cohort study", The Lancet, vol. 358, no. 9285, pp. 861-865, 2001. (Pubitemid 32900566)
70. F. Osman, M. D. Gammage, and J. A. Franklyn, "Hyperthyroidism and cardiovascular morbidity and mortality", Thyroid, vol. 12, no. 6, pp. 483-487, 2002. (Pubitemid 34721544)
71. The Coronary Drug Project Research Group, "The coronary drug project. Findings leading to further modifications of its protocol with respect to dextrothyroxine", Journal of the American Medical Association, vol. 220, no. 7, pp. 996-1008, 1972.
72. W. F. Young Jr., C. A. Gorman, N. S. Jiang, D. Machacek, and I. D. Hay, "L-thyroxine contamination of pharmaceutical D-thyroxine: probable cause of therapeutic effect", Clinical Pharmacology and Therapeutics, vol. 36, no. 6, pp. 781-787, 1984. (Pubitemid 15243797)
73. M. A. Portman, A. Slee, A. K. Olson et al., "Triiodothyronine supplementation in infants and children undergoing cardiopulmonary bypass (TRICC): a multicenter placebocontrolled randomized trial: age analysis", Circulation, vol. 122, no. 11, supplement 1, pp. S224-S233, 2010.
74. J. D. Klemperer, I. Klein, M. Gomez et al., "Thyroid hormone treatment after coronary-artery bypass surgery", The New England Journal of Medicine, vol. 333, no. 23, pp. 1522-1527, 1995.
75. J. D. Klemperer, J. Zelano, R. E. Helm et al., "Triiodothyronine improves left ventricular function without oxygen wasting effects after global hypothermic ischemia", Journal of Thoracic and Cardiovascular Surgery, vol. 109, no. 3, pp. 457-465, 1995.
76. A. Pingitore, E. Galli, A. Barison et al., "Acute effects of triiodothyronine (T3) replacement therapy in patients with chronic heart failure and low-T3 syndrome: a randomized, placebo-controlled study", Journal of Clinical Endocrinology and Metabolism, vol. 93, no. 4, pp. 1351-1358, 2008. (Pubitemid 351519732)
77. F. S. Malik, M. R. Mehra, P. A. Uber, M. H. Park, R. L. Scott, and C. H. van Meter, "Intravenous thyroid hormone supplementation in heart failure with cardiogenic shock", Journal of Cardiac Failure, vol. 5, no. 1, pp. 31-37, 1999. (Pubitemid 29149086)
78. M. A. Hamilton, L. W. Stevenson, G. C. Fonarow et al., "Safety and hemodynamic effects of intravenous triiodothyronine in advanced congestive heart failure", The American Journal of Cardiology, vol. 81, no. 4, pp. 443-447, 1998. (Pubitemid 28099535)
79. P. Moruzzi, E. Doria, and P. G. Agostoni, "Medium-term effectiveness of L-thyroxine treatment in idiopathic dilated cardiomyopathy", American Journal of Medicine, vol. 101, no. 5, pp. 461-467, 1996. (Pubitemid 126335965)
80. G. Iervasi, M. Emdin, R. M. P. Colzani et al., "Beneficial effects of long-term triiodothyronine (T3) infusion in patients with advanced heart failure and low T3 syndrome", in Proceedings of the 2nd International Congress on Heart Disease-New Trends in Research, Diagnosis and Treatment, A. Kimchi, Ed., pp. 549-553, MedimondMedical Publications, Washington, DC, USA, 2001.
81. M. G. Trivieri, G. Y. Oudit, R. Sah et al., "Cardiac-specific elevations in thyroid hormone enhance contractility and prevent pressure overload-induced cardiac dysfunction", Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 15, pp. 6043-6048, 2006.
82. D. D. Belke, B. Gloss, E. A. Swanson, and W. H. Dillmann, "Adeno-associated virus-mediated expression of thyroid hormone receptor isoforms-α1 and -β1 improves contractile function in pressure overload-induced cardiac hypertrophy", Endocrinology, vol. 148, no. 6, pp. 2870-2877, 2007. (Pubitemid 46984823)
83. P. Moruzzi, E. Doria, P. G. Agostoni, V. Capacchione, and P. Sganzerla, "Usefulness of L-thyroxine to improve cardiac and exercise performance in idiopathic dilated cardiomyopathy", The American Journal of Cardiology, vol. 73, no. 5, pp. 374-378, 1994. (Pubitemid 24068204)
84. H. Degens, A. J. Gilde, M. Lindhout, P. H. M. Willemsen, G. J. van der Vusse, and M. van Bilsen, "Functional and metabolic adaptation of the heart to prolonged thyroid hormone treatment", American Journal of Physiology, vol. 284, no. 1, pp. H108-H115, 2003. (Pubitemid 36076276)
85. E. A. Boehm, B. E. Jones, G. K. Radda, R. L. Veech, and K. Clarke, "Increased uncoupling proteins and decreased efficiency in palmitate-perfused hyperthyroid rat heart", American Journal of Physiology, vol. 280, no. 3, pp. H977-H983, 2001.
86. G. D. Pennock, T. E. Raya, J. J. Bahl, S. Goldman, and E. Morkin, "Cardiac effects of 3, 5-diiodothyropropionic acid, a thyroid hormone analog with inotropic selectivity", Journal of Pharmacology and Experimental Therapeutics, vol. 263, no. 1, pp. 163-169, 1992.
87. X. Wang, W. Zheng, L. P. Christensen, and R. J. Tomanek, "DITPA stimulates bFGF, VEGF, angiopoietin, and Tie-2 and facilitates coronary arteriolar growth", American Journal of Physiology, vol. 284, no. 2, pp. H613-H618, 2003. (Pubitemid 36142889)
88. E. Morkin, G. Pennock, P. H. Spooner, J. J. Bahl, K. Underhill Fox, and S. Goldman, "Pilot studies on the use of 3, 5-diiodothyropropionic acid, a thyroid hormone analog, in the treatment of congestive heart failure", Cardiology, vol. 97, no. 4, pp. 218-225, 2002.
89. S. Goldman, M. McCarren, E. Morkin et al., "DITPA (3, 5-diiodothyropropionic acid), a thyroid hormone analog to treat heart failure: phase II trial veterans affairs cooperative study", Circulation, vol. 119, no. 24, pp. 3093-3100, 2009.
90. A. Pingitore, G. Iervasi, and M. A. Gerdes, "Letter by Pingitore et al regarding article, "DITPA (3, 5-diiodothyropropionic acid), a thyroid hormone analog to treat heart failure: phase II trial Veterans Affairs cooperative study"", Circulation, vol. 121, no. 10, e240, 2010.
91. H. Mizuma, M. Murakami, and M. Mori, "Thyroid hormone activation in human vascular smooth muscle cells: expression of type II iodothyronine deiodinase", Circulation Research, vol. 88, no. 3, pp. 313-318, 2001. (Pubitemid 32173755)
92. A. Colantuoni, P. L. Marchiafava, D. Lapi, F. S. Forini, and G. Iervasi, "Effects of tetraiodothyronine and triiodothyronine on hamster cheek pouch microcirculation", American Journal of Physiology, vol. 288, no. 4, pp. H1931-H1936, 2005. (Pubitemid 40418023)
93. A. M. Gerdes and G. Iervasi, "Thyroid replacement therapy and heart failure", Circulation, vol. 122, no. 4, pp. 385-393, 2010.
94. J. A. Ezekowitz, P. Kaul, J. A. Bakal, P. W. Armstrong, R. C. Welsh, and F. A. McAlister, "Declining in-hospital mortality and increasing heart failure incidence in elderly patients with first myocardial infarction", Journal of the American College of Cardiology, vol. 53, no. 1, pp. 13-20, 2009.
95. T. M. Khumri, K. J. Reid, M. Kosiborod, J. A. Spertus, and M. L. Main, "Usefulness of left ventricular diastolic dysfunction as a predictor of one-year rehospitalization in survivors of acute myocardial infarction", The American Journal of Cardiology, vol. 103, no. 1, pp. 17-21, 2009.